Revenue Showdown: Amgen Inc. vs. Exelixis, Inc.

In the competitive landscape of biotechnology, revenue generation is a key indicator of a company's market strength. Over the past decade, Amgen Inc. has consistently outperformed Exelixis, Inc. in terms of revenue. From 2014 to 2023, Amgen's revenue grew by approximately 40%, reaching a peak of $28.19 billion in 2023. In contrast, Exelixis, Inc. saw a significant increase in revenue, growing over 70 times from $25 million in 2014 to $1.83 billion in 2023. Despite this impressive growth, Exelixis's revenue remains a fraction of Amgen's, highlighting the latter's dominance in the industry. This data underscores the importance of scale and market presence in the biotech sector, where Amgen continues to leverage its established position to maintain a substantial lead over emerging competitors like Exelixis.